DMCAF - DiaMedica Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2660
-0.0143 (-5.12%)
As of 3:59PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.2803
Open0.0000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume119,150
Market Cap40.245M
Beta (3Y Monthly)-0.37
PE Ratio (TTM)N/A
EPS (TTM)-0.045
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING

    DiaMedica Therapeutics Inc. (“DiaMedica”) (DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its initial public offering in the United States of 4,100,000 of its common shares at a price to the public of $4.00 per share. All of the common shares are being offered by DiaMedica. The common shares are expected to begin trading December 7, 2018 on The Nasdaq Capital Market under the symbol “DMAC.” The offering is expected to close on December 11, 2018, subject to the satisfaction of customary closing conditions.

  • GlobeNewswire28 days ago

    DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation

    DiaMedica Therapeutics Inc. (TSX Venture:DMA) (DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list its common shares on The Nasdaq Capital Market. In connection with the planned U.S. listing, the Company, as authorized by its shareholders on November 6, 2018, is implementing a consolidation of its outstanding common shares. “We have made significant progress in positioning DM199 to treat patients with stroke and kidney diseases, including having recently announced a partnership with Ahon Pharmaceuticals, a subsidiary of Fosun Pharmaceuticals, for the treatment of acute ischemic stroke in China in an effort to deliver value to our shareholders,” said Rick Pauls, DiaMedica’s President and Chief Executive Officer.  “This year, we have initiated a Phase II clinical study in patients who have suffered from an acute ischemic stroke and we are about to initiate a clinical study in patients with chronic kidney disease.

  • GlobeNewswirelast month

    DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders

    MINNEAPOLIS, Nov. 06, 2018 -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its.

  • GlobeNewswire2 months ago

    DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke

    Ahon Pharmaceutical Co Ltd.(Ahon Pharma), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd, (Fosun Pharma, HKG: 02196 and SHA: 600196) and DiaMedica Therapeutics Inc. (TSX Venture: DMA and OTCQB: DMCAF) today entered into a license and collaboration agreement, which allows Ahon to have exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R.  Fosun Pharma is one of China’s largest pharmaceutical firms with annual sales of more than USD$2 billion and an extensive related hospital sales force.

  • Zacks Small Cap Research6 months ago

    DMA.V: What Does the Shanghai Pharma Acquisition Mean to DiaMedica?

    On May 21, 2018, Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH, 2607.HK) announced that the Company entered into a Share Purchase Agreement with Takeda  Pharma AG. Pursuant to the agreement, Shanghai Pharma, through its Hong Kong subsidiary Shanghai Pharmaceuticals (HK), will acquire 100% equity interest of a wholly-owned subsidiary of  Takeda  AG with a consideration of US$144 million, resulting in its indirect acquisition of 26.34% shares of  Techpool Bio-pharma Co., Ltd. (Techpool). Upon completion of the Proposed Acquisition, the shareholding in Techpool  by Shanghai Pharma will be increased from 40.80% to 67.14% and Shanghai Pharma would achieve absolute control of Techpool.

  • ACCESSWIRE8 months ago

    DiaMedica to Present at the MicroCap Conference on April 10th in New York City at the Essex House

    MINNEAPOLIS, MN / ACCESSWIRE / April 3, 2018 / DiaMedica Therapeutics Inc. (''DiaMedica'') (TSX-V: DMA) (OTCQB: DMCAF), today announced that Mr. Rick Pauls, President and CEO, will present at The MicroCap ...

  • Zacks Small Cap Researchlast year

    V.DMA: New Financing Boosts Balance Sheet and Validates Clinical Programs

    On Dec. 13, 2017, DiaMedica (TSX:DMA.V) announced a non-brokered private placement. Per the news release, each unit included one common share and one-half of one common share purchase warrant. This share offering was offered on a non-brokered private placement basis to accredited investors.